Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories
-
Intellia Therapeutics (NTLA) PT Raised to $27 at Chardan
-
Chardan Capital Markets Upgrades Allurion Technologies (ALUR) to Buy
-
VivoPower terminates at-the-market equity offering agreement
-
Chardan Capital Markets Upgrades Korro Bio Inc. (KRRO) to Buy
-
Aldabra 4 completes $300.15 million IPO on NASDAQ
-
Aldabra 4 prices $261 million IPO at $10 per unit
-
Chardan Capital Markets Starts Alumis Inc (ALMS) at Buy
-
ZOOZ Reports Preliminary 2025 Financial Information, Cash and Bitcoin Positions and Additional Corporate Updates
-
Chardan Capital Markets Starts ZOOZ Strategy (ZOOZ) at Buy
-
Black Spade Acquisition III closes $172.5 million IPO on NYSE
-
Black Spade Acquisition III Co Announces Closing of $172.5 Million Initial Public Offering, Including Full-Exercise of Over-Allotment Option
-
Black Spade Acquisition III prices $150 million IPO
-
Black Spade Acquisition III Co Announces Pricing of $150 Million Initial Public Offering
-
Chardan Capital Markets Assumes Reviva Pharmaceuticals (RVPH) at Buy
-
Chardan Capital Markets Assumes Stoke Therapeutics (STOK) at Buy
-
Chardan Capital Markets Assumes Alto Neuroscience (ANRO) at Buy
-
QumulusAI files for direct listing on Nasdaq
-
Chardan Capital Markets Starts Hyperion DeFi, Inc. (HYPD) at Buy
-
Chardan Capital Markets Starts Hyperliquid Strategies, Inc. (PURR) at Buy
-
Chardan Capital Markets Starts Kalaris (KLRS) at Buy
-
Chardan Capital Markets Starts Annexon Biosciences (ANNX) at Buy
-
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
-
Palvella Therapeutics (PVLA) PT Raised to $174 at Chardan Capital Markets
-
Lion Group raises $10 million, allocates $8 million for bitcoin purchase
-
Lion Group Holding Ltd Announces $10 Million Private Placement for the acquisition of Bitcoin (BTC)
-
Hyperliquid Strategies completes business combination with Sonnet BioTherapeutics
-
Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
-
Senti Bio reports Q3 financial results, confirms ASH data presentation
-
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual
-
Chardan Capital Markets Downgrades Korro Bio Inc. (KRRO) to Neutral
-
Corvex to merge with Movano in all-stock deal creating AI infrastructure firm
-
CORVEX TO GO PUBLIC IN ALL-STOCK MERGER WITH MOVANO, CREATING A PURE-PLAY PLATFORM FOR SECURE AI INFRASTRUCTURE AND HIGH-PERFORMANCE INFERENCE
-
Monopar Therapeutics (MNPR) PT Raised to $100 at Chardan Capital Markets
-
Chardan Capital Markets Downgrades Avidity Biosciences (RNA) to Neutral
-
Alps Announces Closing of Business Combination with Globalink Investment Inc.
-
Chardan Capital Markets Starts Kodiak AI (KDK) at Buy
-
Chardan Capital Markets Downgrades Avidity Biosciences (RNA) to Neutral
-
Chardan Capital Markets Downgrades Adverum Biotechnologies (ADVM) to Neutral
-
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
-
Healios K.K. to Present at Chardan’s 9th Annual Genetic Medicines Conference
-
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
-
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
-
Avidity Biosciences to Participate in Upcoming Investor Conference
-
Chardan Capital Markets Starts Opus Genetics (IRD) at Buy
-
Beacon Therapeutics to Participate in Chardan’s 9th Annual Genetic Medicines Conference
-
REGENXBIO to Participate in Upcoming Investor Conferences
-
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
-
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
-
4DMT to Participate in Chardan's 9th Annual Genetic Medicines Conference
-
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference

